Heparanase processing by lysosomal/endosomal protein preparation  by Cohen, Esti et al.
FEBS Letters 579 (2005) 2334–2338 FEBS 29459Heparanase processing by lysosomal/endosomal protein preparation
Esti Cohena, Ruth Atzmonb, Israel Vlodavskya,*, Neta Ilana
a Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel
b Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
Received 4 January 2005; revised 1 March 2005; accepted 14 March 2005
Available online 25 March 2005
Edited by Lukas HuberAbstract Heparanase is an endo-b-glucuronodase involved in
cleavage of heparan sulfate side chains, activity that is strongly
implicated in cell dissemination associated with tumor metastasis
and inﬂammation. Heparanase is ﬁrst synthesized as a latent
65 kDa precursor that is converted into an active enzyme upon
proteolytic processing. Previously, we have reported that eleva-
tion of the lysosomal pH results in complete inhibition of hepa-
ranase processing, suggesting that lysosomal protease(s) and
acidic pH conditions are required for heparanase processing.
Here, we adopted a cell fractionation approach and provide evi-
dence that incubation of the pro-enzyme with lysosome/endo-
some, but not with cytoplasmic fractions resulted in processing
and activation of the 65 kDa latent heparanase. Moreover, while
the water soluble lysosome/endosome fraction exhibited no
apparent processing activity, heparanase processing by the water
insoluble lysosome/endosome membrane fraction was readily de-
tected and exhibited the expected pH dependency.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Enzymatic cleavage of heparan sulfate proteoglycans
(HSPG) by the endoglycosidase heparanase is thought to play
a decisive role in the disassembly of basement membranes and
extracellular matrix (ECM) by invading tumor cells, resulting
in metastatic spread [1,2]. Similarly, heparanase activity has
been shown to facilitate cell invasion associated with autoim-
munity, inﬂammation and angiogenesis [3–5]. More recently,
heparanase upregulation was detected in a variety of human
primary tumors [1,5], as well as in several other human disor-
ders [6–8]. These results and the occurrence of a single func-
tional heparanase gene [9–11] suggest that heparanase may
be an attractive target for the development of anticancer and
anti inﬂammatory therapies. The heparanase cDNA encodes
for a polypeptide of 543 amino acids that appears as a
65 kDa protein in SDS–PAGE and represents the latent hep-
aranase precursor. The protein undergoes proteolytic process-
ing yielding an 8 kDa polypeptide at the N-terminus and a
50 kDa polypeptide at the C-terminus [5,12] that heterodimer-
ize to form the active heparanase enzyme [13,14]. The prote-*Corresponding author. Fax: +972 4 8523947.
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not been identiﬁed so far. We have recently reported that ele-
vation of the lysosome pH by a speciﬁc inhibitor of the vacu-
olar proton pump (baﬁlomycin A) is suﬃcient to completely
block heparanase processing [15], suggesting that endolysoso-
mal proteolysis and acidic pH conditions [16] are required
for heparanase processing. Here, we took this notion one step
further and established a cell fractionation approach combined
with an in vitro model system to study heparanase processing.
We provide evidence that incubation with lysosome/endosome,
but not with cytoplasmic fractions results in processing and
activation of the latent 65 kDa heparanase precursor.2. Materials and methods
2.1. Antibodies and reagents
Antibody # 1453 was raised against the entire 65 kDa heparanase
precursor isolated from the conditioned medium of heparanase-trans-
fected 293 cells [17]. Anti-Myc epitope tag, anti-lysosomal-associated
membrane protein (LAMP) and anti-cathepsin D monoclonal antibod-
ies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The latent 65 kDa heparanase precursor was puriﬁed from the condi-
tioned medium of heparanase-transfected 293 cells, kindly provided by
Dr. H-Q Miao (ImClone Systems Inc, New York, NY), as described
[15,17,18].
2.2. Cell culture
Human H1299 lung carcinoma, and HCT116 colon carcinomas and
Chinese hamster ovary (CHO) K1 cells were purchased from the
American Type Culture Collection (ATCC) and were grown in Dul-
beccos modiﬁed Eagles medium (DMEM) supplemented with 10%
FCS and antibiotics.
2.3. Cell fractionation
Cellular fractionation was carried out essentially as described by
Schroter et al. [19], with minor modiﬁcations [20]. Brieﬂy, cells
(5 · 107) were harvested by trypsin and washed twice with PBS. The
cell pellet was resuspended with 5 ml homogenization buﬀer (10 mM
Tris/acetic acid buﬀer, pH 7, supplemented with 250 mM sucrose)
and homogenized by 10 strokes in a 10 ml Potter–Elvehjem-homoge-
nizer. The cell homogenate was centrifuged at 2000 · g for 10 min to
pellet cell debris and the supernatant was collected and centrifuged
at 4000 · g for 10 min to pellet nuclei and cell membranes. The super-
natant was collected and centrifuged at 100000 · g for 20 min to pellet
lysosomes and endosomes. The supernatant was carefully removed and
the lysosome/endosome pellet was resuspended in homogenization buf-
fer and stored at 80 C until use. The supernatant was centrifuged
further at 400000 · g for 30 min to pellet microsomes. The ﬁnal super-
natant was considered as a highly puriﬁed cytosolic fraction. Lyso-
some/endosome water-soluble and insoluble fractions were obtained
by extracting the lysosome/endosome pellet with distilled water for
5 min, followed by centrifugation at 100000 · g for 20 min. The super-
natant constituted the lysosome-soluble and the pellet constituted the
lysosome-insoluble membrane fractions. Both fractions were collected
and stored at 80 C until use. All procedures were carried out at 4 C.blished by Elsevier B.V. All rights reserved.
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Recombinant heparanase (50 ng) was incubated with 30 lg protein
of the indicated cellular fraction in reaction buﬀer (20 mM phos-
phate/citrate buﬀer supplemented with 50 mMNaCl and 1 mM CaCl2)
at 37 C for 60 min, unless indicated otherwise. The reaction pH was
adjusted by citrate ions and the ﬁnal volume was 100 ll. In order to
evaluate heparanase processing, samples were ﬁrst subjected to pre-
clearing by concanavalin (Con) A–Sepharose beads. Processing reac-
tion was brought to a volume of 1 ml with serum-free DMEM, 20 ll
ConA–Sepharose beads (Amersham, UK) were added and the tubes
were rotated for 2 h at 4 C, followed by centrifugation. The superna-
tant was aspirated, sample buﬀer was added onto the beads and fol-
lowing boiling for 5 min, samples were subjected to SDS–PAGE.
Heparanase processing was evaluated by immunoblotting with anti-
heparanase antibodies, essentially as described [13,15,17,20].Fig. 1. Heparanase processing and activation by lysosomal/endosomal2.5. Heparanase activity assay
Preparation of ECM-coated dishes and determination of heparanase
activity were performed as described in detail elsewhere [13,21]. Pro-
cessing reactions were adjusted to a volume of 1 ml with heparanase
reaction buﬀer (20 mM phosphate/citrate buﬀer, pH 5.8, 50 mMNaCl,
1 mM CaCl2, and 1 mM DTT), applied onto
35S-labeled ECM and
incubated for 18 h at 37 C. Degradation fragments of HS side chains
were eluted at 0.5 < Kav < 0.8 (peak II, fractions 15–30). Nearly intact
HSPGs were eluted just after the Vo (Kav < 0.2, peak I, fractions 3–15).
These high molecular weight products are likely released by proteases
that cleave the HSPG core protein.fraction. (A) CHO K1 cells were fractionated into lysosomal/endo-
somal (Ly) and cytosolic (Cy) fractions as described in Section 2, and
30 lg of each fraction were incubated with puriﬁed 65 kDa heparanase
precursor. After incubation (1 h, 37 C) at the indicated pH, samples
were pre-absorbed to ConA–Sepharose beads and analyzed by
immunoblotting with anti-heparanase antibodies. Note that the
lysosomal/endosomal fraction (Ly) contained a non-speciﬁc higher
molecular weight band. (B) Heparanase processing was carried out at
pH 4 with the same fractions as in (A), except that 35S-methionine-
labeled latent heparanase was used as the precursor. (C) Heparanase
activity. Heparanase processing was carried out at pH 4 as described in
(A) and heparanase activity of the latent 65 kDa heparanase precursor
(*), cytosolic preparation before (m) and after (·) incubation with
latent heparanase, and lysosomal/endosomal preparation before (r)
and after (j) incubation with latent heparanase, was determined using
sulfate labeled ECM as described in Section 2. Note heparanase
activity in the lysosomal/endosomal preparation prior to incubation
with latent heparanase which is markedly increased upon incubation
and processing of the added latent heparanase protein.3. Results
3.1. Lysosomal proteins are capable of heparanase processing
Similar to several other classes of enzymes, heparanase is
ﬁrst synthesized as a latent 65 kDa enzyme that is subse-
quently subjected to processing, which results in active
50 + 8 kDa heparanase heterodimer [12–14]. The enzymatic
machinery that is responsible for heparanase processing has
not been identiﬁed. Recently, we have shown that elevation
of lysosomal pH in cells treated with chloroquine or baﬁlo-
mycin A signiﬁcantly inhibits heparanase processing, result-
ing in accumulation of the latent 65 kDa protein [15]. This
observation led us to suggest that heparanase processing oc-
curs in the lysosome. In order to study heparanase processing
further, CHO K1 cells that are capable of heparanase pro-
cessing and thus express the relevant protease(s) [20] were
subjected to organelle fractionation by diﬀerential centrifuga-
tion [19,20]. Addition of puriﬁed 65 kDa heparanase precur-
sor to the lysosome/endosome (Ly) or cytoplasmic (Cy)
fractions under neutral pH conditions (pH 7) resulted in no
detectable heparanase processing (Fig. 1A). Heparanase pro-
cessing by the lysosomal/endosomal fraction became evident
upon lowering the reaction pH to 5, and further heparanase
processing was noted at pH 4 (Fig. 1A, Ly). By contrast, hep-
aranase processing into low molecular weight bands was not
detected upon lowering the pH of the cytoplasmic prepara-
tion (Fig. 1A, Cy). In order to further conﬁrm that heparan-
ase processing is restricted to lysosomes, and to eliminate
non-speciﬁc bands that often appear in immunoblot analysis,
heparanase was puriﬁed from the conditioned medium of 35S-
methionine-labeled cells. Processing of the radiolabeled hepa-
ranase was clearly observed upon incubation (1 h, 37 C) with
the lysosomal/endosomal, but not cytoplasmic, preparations
(Fig. 1B). Moreover, processing by the lysosomal/endosomal
fraction yielded enzymatically active heparanase protein (Fig.
1C), supporting the biological relevance of this in vitro pro-
cessing system.3.2. Heparanase processing by lysosomal membrane proteins
We next extracted the lysosomal/endosomal fraction with
distilled water followed by high-speed centrifugation to distin-
guish between water-soluble proteins present in the lysosome/
endosome lumen (supernatant, Ly-s) and water-insoluble,
lysosomal/endosomal-membrane (Ly-m) proteins in the pellet.
Immunoblotting with anti lysosomal-associated membrane
protein (LAMP) antibodies revealed a high reactivity in the
lysosomal-membrane (Ly-m) fraction extracted from H1299
non-small cell lung carcinoma (Fig. 2A, upper panel) and
HCT116 colon carcinoma (Fig. 2A, second panel) cells. By
contrast, only faint bands of LAMP were detected in the lyso-
some soluble (Ly-s) and the cytoplasmic (Cy) fractions. In
addition, cathepsin D, a marker for water-soluble lysosome
proteins was not detected in the lysosome-membrane fraction,
but was highly abundant in the soluble fraction (Fig. 2A, third
panel), indicating that this extraction procedure practically
separates membrane and non-membrane lysosomal/endosomal
proteins. Both H1299 and HCT116 cells exhibited high levels
of heparanase activity (data not shown), and HCT116
cells have been used in the past as a source for heparanase
Fig. 2. Heparanase processing and activation by lysosomal-membrane preparation. (A) Lysosome/endosome fractionation. The lysosome/endosome
fraction was incubated with distilled water in order to extract soluble, lumen-containing proteins that remain in the supernatant following
centrifugation at 100000 · g (Ly-s), and insoluble membrane proteins remaining in the pellet (Ly-m). 30 lg of lysosome and cytosolic (Cy) fractions
obtained from H1299 non-small cell lung carcinoma (upper panel) and HCT116 colon carcinoma cells (second panel) were immunoblotted with anti-
LAMP (a marker for lysosome membrane) antibodies. Note abundant LAMP reactivity in the lysosome-membrane (Ly-m), but not in the lysosome-
soluble (Ly-s) preparation. Similarly, HCT116 cell fractions were immunoblotted with anti cathepsin D antibodies (third panel), a soluble lysosome/
endosome component. 3 mg of each fraction obtained from HCT116 cells was ﬁrst pre-absorbed on ConA–Sepharose beads in order to bind and
concentrate the heparanase protein and remove non-speciﬁc bands, followed by immunoblotting with anti-heparanase antibodies (fourth panel).
Note endogenous heparanase localization in the lysosome-soluble (Ly-s) and to a lesser extant to the lysosome-membrane (Ly-m) fractions.
Heparanase (1 lg/ml) was exogenously added to CHO cells, cell fractionation was performed after 4 h and heparanase was detected by
immunoblotting as above (ﬁfth panel). Note that endogenous and exogenously-added heparanase exhibit a similar distribution among the fractions
tested. (B) Heparanase activity. Lysosome-membrane (j), lysosome-soluble (m), and cytosolic (r) fractions extracted from HCT116 cells were
analyzed for heparanase enzymatic activity. Note high heparanase activity in both lysosome fractions, but not in the cytosolic preparation. (C)–(D)
Heparanase processing and activation. (C) Heparanase processing. Latent 65 kDa heparanase protein was left untreated (Con) or was incubated (1 h,
37 C, pH 4) with lysosome/endosome (Ly), lysosome-membrane (Ly-m), lysosome-soluble (Ly-s), or cytosolic (Cy) preparations and heparanase
processing was examined by immunoblotting. Note heparanase processing by the lysosome/endosome (Ly), and lysosome-membrane (Ly-m), but not
by the lysosome-soluble (Ly-s) or cytosolic (Cy) preparations. ns: Non-speciﬁc. (D) Heparanase activity. Similar samples of latent heparanase (m),
lysosome-membrane with (j) or without (r) pro-heparanase, were analyzed for heparanase enzymatic activity. Note low levels of heparanase
activity in the lysosome-membrane preparation and elevation of heparanase activity upon processing of the added proenzyme. (E) pH-dependency.
Lysosome-membrane preparation was incubated (1 h, 37 C) with latent heparanase at the indicated pH and heparanase processing was examined by
immunoblotting. Note heparanase processing under acidic (pH 4 and 5), but not neutral (pH 6 and 7) pH conditions. (F) Time-dependent heparanase
processing. Heparanase precursor was left untreated (Con) or was incubated (37 C, pH 4) with lysosome-membrane preparation for the indicated
time. Heparanase processing was examined by immunoblotting. ns: Non-speciﬁc. Note maximal heparanase processing already 15 min following the
addition of lysosomal-membrane preparation, without signiﬁcant loss or gain at later time points. ns: Non-speciﬁc. (G) Heparanase processing at the
C-terminus. Heparanase precursor was incubated (20 min, 37 C) with lysosome/endosome (pH 4 or 7) or cytosolic (pH 4) preparations and
heparanase processing was examined by immunoblotting with anti-heparanase (upper panel) or anti-Myc (lower panel) antibodies. Note complete
loss of the Myc tag upon incubation with lysosome/endosome preparation at pH 4.
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cytoplasmic fractions derived from HCT116 cells with anti-
heparanase antibodies revealed the presence of the 50 kDa ac-
tive heparanase subunit in both the soluble and insoluble lyso-
somal/endosomal fractions, with the water-soluble fraction
being more intense (Ly-s; Fig. 2A, fourth panel). It should
be noted that high amounts (3 mg) of protein extract were re-
quired for detection of the endogenous heparanase levels. Hep-
aranase was not detected in the cytoplasmic fraction (Cy) of
HCT116 cells, supporting the notion that heparanase is pri-marily stored in endocytic vesicles [15,23,24]. In accordance
with these results, heparanase enzymatic activity was not de-
tected in the cytoplasmic fraction of HCT116 cells, while high
levels of activity were obtained in the lysosomal/endosomal
soluble and insoluble fractions (Fig. 2B). Interestingly, exoge-
nously added heparanase exhibited a similar distribution pat-
tern between the two lysosomal/endosomal fractions (Fig.
2A, ﬁfth panel), suggesting that exogenous heparanase follows
traﬃcking routes similar to the endogenous one [20]. In order
to further localize heparanase-processing activity, the 65 kDa
E. Cohen et al. / FEBS Letters 579 (2005) 2334–2338 2337heparanase precursor was incubated (1 h, 37 C, pH 4) with
lysosomal or cytoplasmic fractions and heparanase processing
was evaluated by immunoblotting with anti-heparanase anti-
bodies. Heparanase processing was evident upon incubation
with whole lysosome/endosome fraction (Ly, Fig. 2C), in
agreement with our previous results (Fig. 1A, pH 4), and even
more so upon incubation with the membrane fraction of the
lysosome/endosome (Ly-m). In contrast, the lysosomal soluble
(Ly-s) or cytosolic (Cy) fractions exhibited no processing activ-
ity (Fig. 2C). Heparanase processing by the lysosomal/endo-
somal membrane fraction yielded an enzymatically active
enzyme (Fig. 2D), conﬁrming its authenticity. Similar to the re-
sults obtained with the whole lysosome/endosome preparation
(Fig. 1A), the lysosome-membrane preparation exhibited opti-
mal activity at pH 4 and no detectable heparanase processing
was evident at pH 6 or 7 (Fig. 2E). These results were con-
ﬁrmed by heparanase activity assay (data not shown). In terms
of kinetics, maximal processing activity was observed already
15 min after incubation of the proenzyme with the lyso-
somal-membrane fraction, with no further increase in process-
ing upon extended incubation periods (Fig. 2F). Heparanase
processing by the lysosomal/endosomal (Fig. 1A) or lyso-
some-membrane (Fig. 2C, E, F) fractions was accompanied
by a shift in molecular weight of the 65 kDa latent protein.
We have recently reported that in addition to cleavage at the
N-terminus, heparanase is also subjected to processing at the
C-terminus, as evident by the loss of a Myc tag introduced
in this location [18,20]. Incubation of heparanase with a lyso-
somal-membrane preparation at pH 4, but not at pH 7, or with
the cytoplasmic preparation, clearly revealed a shift in molec-
ular weight of the 65 kDa heparanase precursor (Fig. 2G,
upper panel). Re-probing the membrane with anti-Myc tag
antibodies indicated that this shift in molecular weight corre-
lated with a loss of the Myc tag (Fig. 2G, lower panel), sug-
gesting that heparanase processing at the N-, as well as the
C-terminus occurs in the lysosome/endosome. Interestingly,
processing at the C-terminus and loss of the Myc tag was less
stringent in its pH requirement and took place at pH 6 or
lower (Fig. 2E). This observation suggests that processing at
the C- and N-terminus are carried out by two diﬀerent prote-
ases at the endocytic pathway.4. Discussion
Heparanase processing and activation are critical regulatory
mechanisms that ultimately dictate heparanase activity and are
thus tempting targets for the development of heparanase inhib-
itors. Recently, we have shown that heparanase processing is
inhibited by reagents that raise the lysosome pH, result that
led us to suggest that heparanase processing occurs in the lyso-
some [15]. In order to validate this notion we established an in
vitro model system and evaluated the ability of cellular frac-
tions to mediate heparanase processing. Clearly, a cytosolic
fraction was devoid of heparanase processing activity. In con-
trast, heparanase processing by lysosomal/endosomal fraction
exhibited pH-dependency and appeared maximal at pH 4,
characteristic of lysosomal proteases [16]. Heparanase process-
ing appeared, however, ineﬃcient under these conditions and
resembled heparanase processing by chloroquine-treated
NMUmouse adenocarcinoma cells [15]. A signiﬁcant improve-ment of processing eﬃciency was observed upon fractionation
of lysosomes/endosomes into water-soluble and -insoluble
(membrane) fractions. While the water-soluble lysosome frac-
tion exhibited no apparent processing activity, processing by
the water-insoluble, lysosome membrane preparation was
readily detected and exhibited the expected pH-dependency
(Fig. 2C and E). In parallel to these biochemical studies, we
have undertaken a molecular biology approach to identify
amino acids critical for heparanase processing and activation.
By a series of point mutations, we have identiﬁed tyrosine156 as
such a critical residue [25]. With this knowledge in hand we
have carefully examined the heparanase processing sequence
and found that an aromatic or bulky hydrophobic amino acid
at position 156 (i.e., Y156 at P2 of the cleavage site YQ:KK) is
typical for cathepsin cleavage. This hypothesis was further
examined by incubation of commercially available cathepsin
with recombinant heparanase, as well as by applying speciﬁc
cathepsin inhibitors, clearly demonstrating that cathepsin-fam-
ily members, primarily cathepsin L and D, mediate heparanase
processing and activation [25]. This compelling evidence sup-
port the notion that heparanase processing and activation oc-
curs in the lysosomal compartment under acidic conditions.
We have recently reported that in addition to processing at
the N-terminus, heparanase is also subjected to processing at
its C-terminus, resulting in loss of a Myc tag introduced at this
location [18,20]. In terms of kinetics, processing at the C-termi-
nus appeared to precede processing at the N-terminus [18],
raising the possibility that C-terminus processing is a prerequi-
site for further processing to occur. According to such a sce-
nario, inhibition of the protease that is responsible for
heparanase processing at the C-terminus will prevent heparan-
ase activity, making the relevant protease an important target.
Heparanase processing in its C-terminus, loss of the Myc tag
and the shift in molecular weight were restricted to the lyso-
somal/endosomal fraction and was not evident upon incuba-
tion with the cytosolic fraction (Figs. 1A and 2C). While N-
terminus processing required low pH values (4–5, Fig. 1A,
Fig. 2E), processing at the C-terminus was observed at pH val-
ues equal or lower than 6 (Fig. 2E). This may suggest that two
proteases which diﬀer in their pH optimum are involved in
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